PL3334721T3 - Antagoniści receptorów cgrp - Google Patents

Antagoniści receptorów cgrp

Info

Publication number
PL3334721T3
PL3334721T3 PL16751123T PL16751123T PL3334721T3 PL 3334721 T3 PL3334721 T3 PL 3334721T3 PL 16751123 T PL16751123 T PL 16751123T PL 16751123 T PL16751123 T PL 16751123T PL 3334721 T3 PL3334721 T3 PL 3334721T3
Authority
PL
Poland
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Application number
PL16751123T
Other languages
English (en)
Inventor
David Andrew Coates
Kevin Charles FORTNER
Steven Marc Massey
Jason Kenneth Myers
Antonio Navarro
Miles Goodman Siegel
Russell Dean Stucky
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3334721T3 publication Critical patent/PL3334721T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL16751123T 2015-08-12 2016-08-05 Antagoniści receptorów cgrp PL3334721T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562203996P 2015-08-12 2015-08-12
US201562266867P 2015-12-14 2015-12-14
EP16751123.7A EP3334721B1 (en) 2015-08-12 2016-08-05 Cgrp receptor antagonists
PCT/US2016/045698 WO2017027345A1 (en) 2015-08-12 2016-08-05 Cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
PL3334721T3 true PL3334721T3 (pl) 2021-10-18

Family

ID=56684300

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16751123T PL3334721T3 (pl) 2015-08-12 2016-08-05 Antagoniści receptorów cgrp

Country Status (36)

Country Link
US (1) US9708297B2 (pl)
EP (1) EP3334721B1 (pl)
JP (1) JP6619503B2 (pl)
KR (1) KR20180030582A (pl)
CN (1) CN107922385B (pl)
AU (1) AU2016304769B2 (pl)
BR (1) BR112018000513A2 (pl)
CA (1) CA2992622A1 (pl)
CL (1) CL2018000290A1 (pl)
CO (1) CO2018001383A2 (pl)
CR (1) CR20180043A (pl)
CY (1) CY1124413T1 (pl)
DK (1) DK3334721T3 (pl)
DO (1) DOP2018000042A (pl)
EA (1) EA201890156A1 (pl)
EC (1) ECSP18009366A (pl)
ES (1) ES2875600T3 (pl)
HK (1) HK1249095A1 (pl)
HR (1) HRP20211013T1 (pl)
HU (1) HUE055609T2 (pl)
IL (1) IL256572A (pl)
LT (1) LT3334721T (pl)
MD (1) MD3334721T2 (pl)
MX (1) MX2018001672A (pl)
NZ (1) NZ738990A (pl)
PE (1) PE20180655A1 (pl)
PH (1) PH12018500282A1 (pl)
PL (1) PL3334721T3 (pl)
PT (1) PT3334721T (pl)
RS (1) RS62041B1 (pl)
SI (1) SI3334721T1 (pl)
SV (1) SV2018005631A (pl)
TN (1) TN2018000026A1 (pl)
TW (1) TWI636041B (pl)
WO (1) WO2017027345A1 (pl)
ZA (1) ZA201800452B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3061653C (en) 2017-05-15 2022-09-06 Eli Lilly And Company Cgrp receptor antagonists
TW201904955A (zh) * 2017-05-15 2019-02-01 美商美國禮來大藥廠 可作為cgrp受體拮抗劑之3-甲基-吡咯啶-2,5-二酮衍生物
WO2019112024A1 (ja) * 2017-12-08 2019-06-13 キッセイ薬品工業株式会社 ピロリジン化合物
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
CN114746409A (zh) * 2019-12-12 2022-07-12 伊莱利利公司 可用作正电子发射断层扫描术的示踪剂化合物的cgrp拮抗剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4376997A (en) * 1996-10-04 1998-05-05 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2007141285A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp-antagonists
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
WO2012129013A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9227972B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
FR3009961A1 (fr) * 2013-08-30 2015-03-06 Ct Hospitalier Universitaire De Clermont Fd Agent bloqueur des canaux cav3 dans le traitement de la douleur
WO2015161011A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Benzamide cgrp receptor antagonists

Also Published As

Publication number Publication date
KR20180030582A (ko) 2018-03-23
CN107922385A (zh) 2018-04-17
SV2018005631A (es) 2018-04-24
ZA201800452B (en) 2019-07-31
ECSP18009366A (es) 2018-04-30
TWI636041B (zh) 2018-09-21
AU2016304769B2 (en) 2018-09-13
DOP2018000042A (es) 2018-10-31
EA201890156A1 (ru) 2018-07-31
ES2875600T3 (es) 2021-11-10
JP2018522933A (ja) 2018-08-16
PT3334721T (pt) 2021-06-17
JP6619503B2 (ja) 2019-12-11
US9708297B2 (en) 2017-07-18
BR112018000513A2 (pt) 2018-09-18
SI3334721T1 (sl) 2021-08-31
NZ738990A (en) 2019-03-29
EP3334721A1 (en) 2018-06-20
CO2018001383A2 (es) 2018-05-21
TW201718481A (zh) 2017-06-01
US20170044138A1 (en) 2017-02-16
CL2018000290A1 (es) 2018-07-13
CY1124413T1 (el) 2022-07-22
HRP20211013T1 (hr) 2021-10-01
AU2016304769A1 (en) 2018-01-25
RS62041B1 (sr) 2021-07-30
PE20180655A1 (es) 2018-04-17
TN2018000026A1 (en) 2019-07-08
IL256572A (en) 2018-02-28
CA2992622A1 (en) 2017-02-16
HUE055609T2 (hu) 2021-12-28
MD3334721T2 (ro) 2021-09-30
WO2017027345A1 (en) 2017-02-16
DK3334721T3 (da) 2021-06-28
LT3334721T (lt) 2021-07-26
EP3334721B1 (en) 2021-04-28
MX2018001672A (es) 2018-05-28
CN107922385B (zh) 2020-09-08
CR20180043A (es) 2018-02-22
PH12018500282A1 (en) 2018-08-13
HK1249095A1 (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
IL258893A (en) Cgrp receptor antagonists
PL3515887T3 (pl) Antagoniści trpv4
IL258737A (en) Antagonists ep4
ZA201800452B (en) Cgrp receptor antagonists
IL251725B (en) Dopamine d3 receptor antagonist compounds
GB201702617D0 (en) Receptor
IL267686A (en) Integrin antagonists
IL244356B (en) Formulations for cgrp receptor antagonists
GB201715008D0 (en) TRPV2 Antagonists
IL258894A (en) Cgrp receptor antagonists
EP3865472C0 (en) THROMBOXANE RECEPTOR ANTAGONISTS
IL252903A0 (en) cgrp antagonist peptides
GB201702174D0 (en) Orexin receptor antagonists
GB201707499D0 (en) Orexin receptor antagonists
GB201507202D0 (en) Receptor tyosine kinase biomarkers
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
ZA201704249B (en) Cgrp antagonist peptides
GB201707504D0 (en) Orexin receptor antagonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
TH1601001484A (th) สูตรผสมสำหรับ cgrp รีเซปเตอร์แอนตะกอนิสต์